Dynavax Technologies Co. (NASDAQ:DVAX) Shares Acquired by GAMMA Investing LLC

GAMMA Investing LLC increased its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 175.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,645 shares of the biopharmaceutical company’s stock after purchasing an additional 1,685 shares during the period. GAMMA Investing LLC’s holdings in Dynavax Technologies were worth $29,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of DVAX. Vanguard Group Inc. increased its stake in Dynavax Technologies by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 9,275,788 shares of the biopharmaceutical company’s stock worth $129,676,000 after buying an additional 128,897 shares in the last quarter. Congress Asset Management Co. MA increased its position in shares of Dynavax Technologies by 1.3% during the first quarter. Congress Asset Management Co. MA now owns 229,980 shares of the biopharmaceutical company’s stock worth $2,854,000 after purchasing an additional 2,845 shares in the last quarter. Diversified Trust Co raised its stake in Dynavax Technologies by 3.2% in the 1st quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock valued at $367,000 after purchasing an additional 925 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Dynavax Technologies by 19.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 140,622 shares of the biopharmaceutical company’s stock valued at $1,745,000 after purchasing an additional 22,548 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in Dynavax Technologies by 4.2% during the 1st quarter. Principal Financial Group Inc. now owns 767,909 shares of the biopharmaceutical company’s stock worth $9,530,000 after purchasing an additional 31,002 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Stock Up 0.3 %

Shares of NASDAQ:DVAX opened at $10.95 on Friday. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.15. The stock has a market cap of $1.43 billion, a P/E ratio of 182.50 and a beta of 1.37. The business has a fifty day moving average of $11.05 and a two-hundred day moving average of $11.27. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. The business had revenue of $73.80 million during the quarter, compared to analysts’ expectations of $76.92 million. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. During the same quarter in the prior year, the company posted $0.03 EPS. On average, research analysts expect that Dynavax Technologies Co. will post 0.16 earnings per share for the current year.

Wall Street Analyst Weigh In

DVAX has been the subject of a number of recent research reports. The Goldman Sachs Group reduced their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.67.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.